Business Of Biotech
The Anti-CDMO with CTMC's Jason Bock, Ph.D. and KSQ's Thomas Leitch
May 20, 2024
Dr. Jason Bock, CEO of CTMC, challenges the CDMO classification for his company. He shares CTMC's mission to aid early clinical-stage firms like KSQ Therapeutics enter their clinical stage successfully. The podcast explores the collaboration between CTMC and KSQ, discussing the challenges and innovations in cell therapy development, experienced groups in the Tills industry uniting, cultural alignment and technical collaborations in biotech partnerships, the power of aligned incentives in collaborations, and excitement in advancing clinical data sets and cell therapies.
57:35
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- CTMC focuses on accelerating cell therapy development through a unique partnership with MD Anderson.
- The collaboration between CTMC and KSQ emphasizes cultural alignment and logistical advantages for advancing till programs.
Deep dives
Origin Story and Partnership Model of CTMC and KSQ
The origin story of CTMC involves the vision to accelerate cell therapy as a field, transitioning from academic science to industrial therapeutic development. Through a partnership with MD Anderson, CTMC focuses on industrializing research concepts and accelerating cell therapy development. On the other hand, KSQ focuses on gene-edited till programs uncovering optimal targets for oncology with promising results and potential therapeutic development.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
